Literature DB >> 23615810

Evolution of Factor V Leiden.

Thijs E van Mens1, Marcel Levi, Saskia Middeldorp.   

Abstract

Factor V Leiden is a procoagulant mutation associated with venous and arterial thrombosis and pregnancy complications. Its high prevalence of 5% in Caucasians suggests that there are evolutionary benefits as well. Carriers are indeed reported to have various advantageous phenotypes related to haemostasis, inflammation and fertility: less acute blood loss; less menstrual blood loss; decreased risk of intracranial haemorrhage; milder phenotypes of haemophilia; higher survival in and lower susceptibility to severe sepsis; higher survival in acute respiratory distress syndrome; less severe diabetic nephropathy and higher fecundity in both men and women. Not all these associations come from high quality adequately powered studies and many have not been confirmed by further research. The evolutionary influence of the alleged associations varies and is difficult to establish, partly due to a shift over time in risk factors of the diseases concerned. For most of the phenotypes possible mechanistic explanations can be provided. The procoagulant phenotype and perhaps also certain pregnancy complications follow from activated protein C (APC) resistance. Elevated APC levels possibly mediate anti-inflammatory effects. Higher sperm counts and more successful embryo implantation seem to play a role in the increased fecundity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23615810     DOI: 10.1160/TH13-02-0115

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  10 in total

Review 1.  Association between the V Leiden G1691A mutation and sudden sensorineural hearing loss in Italian population: a meta-analysis.

Authors:  Jingcheng Shu; Yongfeng Si; Shihua Yin; Meirong He
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-11-30       Impact factor: 2.503

2.  ABO blood group and fertility: a single-centre study.

Authors:  Carlo Mengoli; Carlo Bonfanti; Chiara Rossi; Massimo Franchini
Journal:  Blood Transfus       Date:  2015-04-27       Impact factor: 3.443

3.  Circulating activated protein C in thrombophilia carriers.

Authors:  Thijs E van Mens; Joost C M Meijers; Saskia Middeldorp
Journal:  J Thromb Thrombolysis       Date:  2017-04       Impact factor: 2.300

4.  Survival advantage of heterozygous factor V Leiden carriers in murine sepsis.

Authors:  E Kerschen; I Hernandez; M Zogg; M Maas; H Weiler
Journal:  J Thromb Haemost       Date:  2015-03-31       Impact factor: 5.824

Review 5.  Inherited thrombophilia: a double-edged sword.

Authors:  Saskia Middeldorp
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

6.  Exploratory Investigation of the Plasma Proteome Associated with the Endotheliopathy of Trauma.

Authors:  Joseph D Krocker; Kyung Hyun Lee; Hanne H Henriksen; Yao-Wei Willa Wang; Erwin M Schoof; Sigurdur T Karvelsson; Óttar Rolfsson; Pär I Johansson; Claudia Pedroza; Charles E Wade
Journal:  Int J Mol Sci       Date:  2022-06-01       Impact factor: 6.208

7.  Extracting Complementary Insights from Molecular Phenotypes for Prioritization of Disease-Associated Mutations.

Authors:  Shayne D Wierbowski; Robert Fragoza; Siqi Liang; Haiyuan Yu
Journal:  Curr Opin Syst Biol       Date:  2018-09-17

Review 8.  Causes and consequences of coagulation activation in sepsis: an evolutionary medicine perspective.

Authors:  Maiara Marx Luz Fiusa; Marco Antonio Carvalho-Filho; Joyce M Annichino-Bizzacchi; Erich V De Paula
Journal:  BMC Med       Date:  2015-05-06       Impact factor: 8.775

9.  Fibrinogen as a Pleiotropic Protein Causing Human Diseases: The Mutational Burden of Aα, Bβ, and γ Chains.

Authors:  Elvezia Maria Paraboschi; Stefano Duga; Rosanna Asselta
Journal:  Int J Mol Sci       Date:  2017-12-14       Impact factor: 5.923

10.  Current and future burden of venous thrombosis: Not simply predictable.

Authors:  Luuk J J Scheres; Willem M Lijfering; Suzanne C Cannegieter
Journal:  Res Pract Thromb Haemost       Date:  2018-04-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.